A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.

Autor:	Le TTB; Internal Medicine, Department of Cardiovascular Research, Methodist Hospital, Merrillville, USA., Minh LHN; College of Medicine, Taipei Medical University, Taipei, TWN.; Research Center for Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, Taipei, TWN., Devi P; Internal Medicine, Maimonides Medical Center, New York, USA., Islam N; Internal Medicine, Mymensingh Medical College, Dhaka, BGD.; Internal Medicine, Queens Hospital Center, New York, USA., Sachmechi I; Internal Medicine, Icahn School of Medicine at Mount Sinai/Queens Hospital Center, New York, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jan 01; Vol. 16 (1), pp. e51460. Date of Electronic Publication: 2024 Jan 01 (Print Publication: 2024).
DOI:	10.7759/cureus.51460
Abstrakt:	This report examines a case of systemic hypersensitivity to tirzepatide in a patient with type 2 diabetes. Tirzepatide (Mounjaro®), a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor, has recently gained FDA approval. Additionally, a literature review was conducted to summarize recent research on tirzepatide's effectiveness and safety. A 67-year-old woman, previously treated with basal insulin, metformin, and semaglutide (a GLP-1 agonist), experienced severe disseminated pruritus and a generalized urticarial rash after her first dose of tirzepatide. This reaction, which subsided with antihistamines, raises questions about possible immunoglobulin E-mediated hypersensitivity. The report highlights the need for increased vigilance regarding allergic reactions to new diabetes medications, particularly in the context of GIP/GLP-1 receptor agonists. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Le et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu